Related Experiment Video
Updated: Jul 8, 2026
Generation of Human Brain Organoids for Mitochondrial Disease Modeling
Published on: June 21, 2021
Patient-derived forebrain cortical organoids reveal biphasic tau-MAP6-microtubule axis dysfunction in tauopathy
Xiaohuan Sun1, Skandha Ramakrishnan1, Victor C Ogbolu1
1Department of Neurobiology and Anatomy, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA.
Introduction:
In frontotemporal dementia (FTD), tau detaches from axonal microtubules and forms pathological aggregates. Rather than stabilizing microtubules, tau promotes labile microtubule domains, redefining its role in neurodegeneration and underscoring the need for human models that capture temporal disease progression.
Methods:
Human induced pluripotent stem cells carrying MAPTWT/P301L, MAPTWT/P301S, or MAPTWT/R406W mutations and isogenic controls were differentiated into forebrain cortical organoids (1 to 8 months). Tau isoforms, microtubule dynamics, MAP6 regulation, neuronal activity, tau mRNA stability, and tau pathology were analyzed using biochemical, imaging, and electrophysiological approaches, some of which were benchmarked to postmortem behavorial variant FTD cortex.
Results:
Early-phase tau mutant organoids showed elevated tau, hyperdynamic microtubules, and neuronal hyperexcitability, partially reversible by tau reduction. Late-phase organoids exhibited insoluble tau accumulation, microtubule hyperstability, and neurodegeneration and reactive astrocytes, accompanied by opposing, phase-dependent MAP6 changes.
Discussion:
This work reveals a biphasic tau-MAP6-microtubule mechanism driving tauopathy and establishes these organoids as a platform for phase-specific therapy.
Insights
Frontotemporal dementia (FTD) involves tau pathology. This study reveals a biphasic tau-MAP6-microtubule mechanism in human organoids, offering a platform for phase-specific FTD therapies.
Area of Science:
- Neuroscience
- Stem Cell Biology
- Genetics
Background:
- Frontotemporal dementia (FTD) is characterized by tau detachment from microtubules and aggregation.
- Tau's role in promoting labile microtubule domains contributes to neurodegeneration.
- There is a critical need for human models to study FTD's temporal progression.
Purpose of the Study:
- To investigate the temporal progression of tauopathy using human induced pluripotent stem cell-derived cortical organoids.
- To elucidate the role of tau, MAP6, and microtubule dynamics in FTD pathogenesis.
- To establish a platform for testing phase-specific therapeutic interventions for FTD.
Main Methods:
- Generation of human forebrain cortical organoids from stem cells with MAPT mutations (P301L, P301S, R406W) and isogenic controls.
- Analysis of tau isoforms, microtubule dynamics, MAP6 regulation, neuronal activity, and tau pathology over 1-8 months.
- Utilized biochemical, imaging, and electrophysiological techniques, benchmarked against postmortem FTD cortex.
Main Results:
- Early-phase organoids displayed elevated tau, hyperdynamic microtubules, and neuronal hyperexcitability, partially reversible by tau reduction.
- Late-phase organoids showed insoluble tau, microtubule hyperstability, neurodegeneration, reactive astrocytes, and phase-dependent MAP6 changes.
- Demonstrated a biphasic progression of tauopathy in the organoid model.
Conclusions:
- A biphasic tau-MAP6-microtubule mechanism drives tauopathy in FTD.
- Human cortical organoids serve as a valuable platform for studying FTD's temporal aspects.
- This model enables the development and testing of phase-specific therapies for FTD.
More Related Videos
08:56Modeling Mitochondrial Disease Using Brain Organoids: A Focus on Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes
Published on: October 10, 2025
14:192D and 3D Human Induced Pluripotent Stem Cell-Based Models to Dissect Primary Cilium Involvement during Neocortical Development
Published on: March 25, 2022